Glenn applies his scientific and legal experience to build and protect patent rights for clients innovating in chemistry, biotechnology, and pharmaceutical arenas.

Prior to practicing law, Glenn had a distinguished career as a postdoctoral and startup scientist developing small molecule drugs, nucleic acid technology, and engineered peptide biomolecules. This invaluable R&D experience allows Glenn to deeply understand and protect his clients’ platform technology and innovative products.

Glenn has 15 years of patent prosecution experience and counsels early-stage pharmaceutical and biotechnology clients as they develop platform technology, and identify and develop drug candidates. Glenn also guides pharmaceutical clients during life cycle management and clinical development of FDA-approved or soon-to-be approved small molecule and biologic drugs. Glenn has particular subject matter expertise in the areas of PROTAC and LYTAC degraders, engineered proteins, nucleic acids, D-proteins, small molecule drugs, and therapeutic uses of such molecules.

Glenn’s practice includes due diligence evaluations and preparing opinions of patentability, validity, infringement and enforcement. Glenn has particular expertise developing and executing strategies to build and protect patent portfolios that extend pharmaceutical exclusivity for drug products. To that end Glenn has prepared numerous patent term adjustment petitions and patent term extension applications and conducted Orange Book listing investigations.